Clobazam: pharmacological and therapeutic profile

British Journal of Clinical Pharmacology
G W Hanks


1 Clobazam is a 1,5-benzodiazepine the pharmacological profile of which differs from that of the 1,4 benzodiazepines in that it displays a wide separation of psychosedative or 'tranquillizing' properties from impairment of motor coordination. This is associated with a relative lack of muscle relaxant activity. 2 In man it seems to be an effective anxiolytic agent when given in daily doses of 20-30 mg but produces minimal effects on psychomotor performance at these dose levels. 3 Clobazam has a long elimination half-life of about 18 h; the main metabolite is N-desmethylclobazam. Clobazam seems to share the good safety and tolerability characteristics of the 1,4 benzodiazepines.


Oct 1, 1977·British Journal of Clinical Pharmacology·A N NicholsonC H Clarke
Oct 1, 1977·British Journal of Clinical Pharmacology·I HindmarchA J Hewett
Jul 1, 1978·Journal of Clinical Pharmacology·D R DoongajiS S Thatte
Jun 15, 1978·Psychopharmacology·H J Gerhards
Jan 1, 1979·British Journal of Clinical Pharmacology·D Koeppen
Jan 1, 1979·British Journal of Clinical Pharmacology·H Kuch
Jan 1, 1979·British Journal of Clinical Pharmacology·E Schütz
Jan 1, 1979·British Journal of Clinical Pharmacology·M VolzF Cavagna
Jan 1, 1979·British Journal of Clinical Pharmacology·W RuppO Vanderbeke
Jan 1, 1979·British Journal of Clinical Pharmacology·J R Wittenborn
Jan 1, 1979·British Journal of Clinical Pharmacology·J R WittenbornR J Nash
Jan 1, 1979·British Journal of Clinical Pharmacology·I Hindmarch
Jan 1, 1979·British Journal of Clinical Pharmacology·A N Nicholson
Jan 1, 1979·British Journal of Clinical Pharmacology·B Biehl
Sep 1, 1978·British Journal of Clinical Pharmacology·C M KessonD H Lawson
Oct 19, 1974·Lancet·J M Kellett
Sep 21, 1974·Lancet·P Tyrer


Jun 1, 1994·Pharmacology & Toxicology·S Monjanel-MouterdeJ P Cano
Jan 1, 1984·European Journal of Clinical Pharmacology·H R OchsB Verburg-Ochs
Jan 17, 2012·Expert Opinion on Pharmacotherapy·Melissa GiarratanoSelim R Benbadis
Nov 9, 2011·Advanced Drug Delivery Reviews·Cecilie Johannessen LandmarkTorbjörn Tomson
Apr 4, 2008·Acta Neurologica Scandinavica·J RissS Collins
Feb 1, 1987·British Journal of Clinical Pharmacology·J R HaighM Feely
Aug 12, 2010·Thérapie·Danièle Bentué-FerrerSuivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique
Dec 14, 2011·Expert Review of Neurotherapeutics·Anyzeila DiazSelim R Benbadis

Related Concepts

Anti-Anxiety Effect

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Pediculosis pubis

Pediculosis pubis is a disease caused by a parasitic insect known as Pthirus pubis, which infests human pubic hair, as well as other areas with hair including eye lashes. Here is the latest research.

Rh Isoimmunization

Rh isoimmunization is a potentially preventable condition that occasionally is associated with significant perinatal morbidity or mortality. Discover the latest research on Rh Isoimmunization here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

Enzyme Evolution

This feed focuses on molecular models of enzyme evolution and new approaches (such as adaptive laboratory evolution) to metabolic engineering of microorganisms. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

Alignment-free Sequence Analysis Tools

Alignment-free sequence analyses have been applied to problems ranging from whole-genome phylogeny to the classification of protein families, identification of horizontally transferred genes, and detection of recombined sequences. Here is the latest research.